Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

Rhea-AI Summary

Pliant Therapeutics (PLRX), a clinical stage biotechnology firm, announced its participation in the virtual 2021 RBC Capital Markets Global Healthcare Conference on May 18-19, 2021. CEO Bernard Coulie will engage in a fireside chat on May 18 at 4:15 p.m. EDT, alongside the senior management team for one-on-one meetings with investors. The session will be accessible for 90 days on the company’s website. Pliant focuses on developing therapies for fibrosis, with its leading candidate PLN-74809 showing promise for idiopathic pulmonary fibrosis and primary sclerosing cholangitis.

SOUTH SAN FRANCISCO, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced its participation in the 2021 RBC Capital Markets Global Healthcare Conference to be held virtually from May 18 –19, 2021.

Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, will participate in a virtual fireside chat with RBC’s Brian Abrahams, on Tuesday, May 18, 2021 at 4:15 p.m. EDT / 1:15 p.m. PDT and, along with members of Pliant’s senior management team, will conduct one-on-one meetings with members of the investment community.

The live and archived event can be accessed by visiting the "News & Events" section of the "Investors & Media" page of the Pliant Therapeutics' website at www.pliantrx.com. The event will be available for 90 days.

About Pliant Therapeutics, Inc.

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of α_vß₆ and α_vß₁ integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809 in the lead indications of IPF, PSC. Pliant has also developed PLN-1474, a small-molecule selective inhibitor of α_vß₁ for the treatment of nonalcoholic steatohepatitis, or NASH with liver fibrosis, which Pliant has transferred to Novartis pursuant to our development partnership. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies. For additional information about Pliant Therapeutics, visit www.pliantrx.com and follow us on Twitter, LinkedIn, Facebook, and YouTube.

Investor and Media Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com

FAQ

When is Pliant Therapeutics presenting at the RBC Capital Markets Global Healthcare Conference?

Pliant Therapeutics will present at the conference on May 18, 2021.

Who will represent Pliant Therapeutics at the RBC conference?

CEO Bernard Coulie will participate in a fireside chat at the RBC conference.

What is the focus of Pliant Therapeutics?

Pliant Therapeutics is focused on developing therapeutics for the treatment of fibrosis.

What is PLN-74809 developed by Pliant Therapeutics?

PLN-74809 is an oral small-molecule dual selective inhibitor in development for idiopathic pulmonary fibrosis and primary sclerosing cholangitis.

How can I access the RBC conference presentation by Pliant Therapeutics?

The presentation can be accessed via the 'News & Events' section of Pliant Therapeutics' website.